Cargando…
p53, SKP2, and DKK3 as MYCN Target Genes and Their Potential Therapeutic Significance
Neuroblastoma is the most common extra-cranial solid tumor of childhood. Despite significant advances, it currently still remains one of the most difficult childhood cancers to cure, with less than 40% of patients with high-risk disease being long-term survivors. MYCN is a proto-oncogene implicated...
Autores principales: | Chen, Lindi, Tweddle, Deborah A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3508619/ https://www.ncbi.nlm.nih.gov/pubmed/23226679 http://dx.doi.org/10.3389/fonc.2012.00173 |
Ejemplares similares
-
MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63
por: Gamble, Laura D., et al.
Publicado: (2011) -
Skp2 is a Promising Therapeutic Target in Breast Cancer
por: Wang, Zhiwei, et al.
Publicado: (2012) -
Molecular mechanisms of MYCN-dependent apoptosis and the MDM2–p53 pathway: an Achille’s heel to be exploited for the therapy of MYCN-amplified neuroblastoma
por: Petroni, Marialaura, et al.
Publicado: (2012) -
Targeting the DNA Damage Response for the Treatment of High Risk Neuroblastoma
por: Southgate, Harriet E. D., et al.
Publicado: (2020) -
NLRR1 Is a Potential Therapeutic Target in Neuroblastoma and MYCN-Driven Malignant Cancers
por: Takatori, Atsushi, et al.
Publicado: (2021)